Process is said to accelerate the discovery and design of leads.
Presidio Pharmaceuticals, a specialty pharmaceutical company focused on developing and commercializing small molecule compounds for the treatment of HIV-1 and hepatitis C virus (HCV), and Numerate entered into a research collaboration to discover and develop small molecule inhibitors of HCV.
“Numerate has a promising computational approach that we believe will help expand our HCV portfolio in a highly competitive area encumbered by many patents,” says Richard Colonno, CSO of Presidio. “Numerate’s drug-engineering process addresses the key design criteria in parallel with a focus on delivering advanced lead compounds quickly. The process accelerates the discovery and design of novel leads and reduces the time and cost needed to advance compounds into clinical trials.”
Numerate has developed and extensively validated a drug-engineering platform that rapidly and cost-effectively delivers small molecule therapeutics optimized for efficacy, safety, and patentability, according to Guido Lanza, CEO. Numerate applies this technology to design and develop small molecule drugs in collaboration with a variety of partners and in the advancement of therapeutic programs including a multitargeted therapy for type II diabetes and cardiovascular disease.
